Free Trial

Aridis Pharmaceuticals (ARDS) Stock Price, News & Analysis

-0.01 (-15.75%)
(As of 05/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
419,654 shs
Average Volume
29,577 shs
Market Capitalization
$2.56 million
P/E Ratio
Dividend Yield
Price Target
ARDS stock logo

About Aridis Pharmaceuticals Stock (NASDAQ:ARDS)

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.

ARDS Stock Price History

ARDS Stock News Headlines

Aridis Pharmaceuticals Inc (ARDS)
Aridis Pharmaceuticals Inc ARDS
ARDS Sep 2023 2.500 call
Aridis Pharma (ARDS) Earnings Dates & Reports
Aridis Pharmaceuticals Announces $2 Million Offering
See More Headlines
Receive ARDS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aridis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$3.09 million
Book Value
($1.16) per share


Free Float
Market Cap
$2.56 million
Not Optionable
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Eric J. Patzer Ph.D. (Age 75)
    Founder & Executive Chairman
    Comp: $240k
  • Dr. Vu L. Truong Ph.D. (Age 60)
    Founder, CEO, Chief Scientific Officer & Director
    Comp: $631.65k
  • Dr. Hasan Jafri M.D. (Age 57)
    Chief Medical Officer
    Comp: $559.36k
  • Ms. Tamara S. Allen (Age 57)
    Vice President of Finance
  • Mr. Jeffrey J. Fessler Esq. (Age 61)
    J.D., Acting General Counsel

ARDS Stock Analysis - Frequently Asked Questions

Should I buy or sell Aridis Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARDS shares.
View ARDS analyst ratings
or view top-rated stocks.

What is Aridis Pharmaceuticals' stock price target for 2024?

1 brokers have issued 1 year price objectives for Aridis Pharmaceuticals' shares. Their ARDS share price targets range from $2.00 to $2.00. On average, they expect the company's share price to reach $2.00 in the next twelve months. This suggests a possible upside of 3,638.3% from the stock's current price.
View analysts price targets for ARDS
or view top-rated stocks among Wall Street analysts.

How have ARDS shares performed in 2024?

Aridis Pharmaceuticals' stock was trading at $0.0701 at the beginning of the year. Since then, ARDS stock has decreased by 23.7% and is now trading at $0.0535.
View the best growth stocks for 2024 here

How were Aridis Pharmaceuticals' earnings last quarter?

Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) posted its earnings results on Wednesday, November, 10th. The company reported ($1.94) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $1.43. The business earned $0.52 million during the quarter.

What other stocks do shareholders of Aridis Pharmaceuticals own?
When did Aridis Pharmaceuticals IPO?

Aridis Pharmaceuticals (ARDS) raised $28 million in an initial public offering on Tuesday, August 14th 2018. The company issued 2,000,000 shares at a price of $13.00-$15.00 per share. Cantor served as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.

How do I buy shares of Aridis Pharmaceuticals?

Shares of ARDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARDS) was last updated on 5/24/2024 by Staff

From Our Partners